Abstract| Volume 103, P89-90, September 2017

Clinical evaluation of the NK3 receptor antagonist fezolinetant (a.k.a. ESN364) for the treatment of menopausal hot flashes

      Context: NK3 receptor (“NK3”; TACR3) signaling is implicated in the etiology of hot flashes by the clinical pharmacology of neurokinin B (NKB) [ ], neuroanatomical evidence for hypertrophy of NKB-expressing neurons in menopausal women [ ], and association between risk of vasomotor symptoms and genetic variation in TACR3 [ ]. Fezolinetant is an NK3 antagonist demonstrated to safely modulate hormone biomarkers in premenopausal women [
      • Fraser G.L.
      • et al.
      ]. Here, we present clinical trial results for fezolinetant in the treatment of menopausal hot flashes (“HF”).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jayasena C.N.
        • et al.
        Sci Rep. 2015; 5
        • Rance N.E.
        Peptides. 2009; 30: 111-122
        • Crandall C.J.
        • et al.
        Menopause. 2016;
        • Fraser G.L.
        • et al.
        J Clin Endocrinol Metab. 2016;